![Robert Cuthbertson](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Robert Cuthbertson
Direktor/Vorstandsmitglied bei
ZENYTH THERAPEUTICS LIMITED
Vermögen: 6 Mio $ am 30.06.2026
Profil
Gegenwärtig ist Andrew Cuthbertson Chief Scientific Officer & Executive Director bei CSL Ltd. und Chief Scientific Officer von CSL Behring LLC (einer Tochtergesellschaft von CSL Ltd.). Er ist außerdem Mitglied des Vorstands von CSL Innovation Pty Ltd., des Centre for Eye Research Australia und des Grattan Institute sowie Ratsmitglied an der Universität von Melbourne. Andrew Cuthbertson war zuvor als Senior Scientist bei Genentech, Inc. tätig.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
CSL LIMITED 0.01% | 17.02.2026 | 71’128 ( 0.01% ) | 6 Mio $ | 30.06.2026 |
Aktive Positionen von Robert Cuthbertson
| Unternehmen | Position | Beginn |
|---|---|---|
| ZENYTH THERAPEUTICS LIMITED | Direktor/Vorstandsmitglied | - |
| CSL LIMITED | Direktor/Vorstandsmitglied | 17.10.2018 |
CSL Behring LLC
 CSL Behring LLC BiotechnologyHealth Technology Manufactures and markets plasma protein products | Direktor/Vorstandsmitglied | 01.01.2018 |
University of Melbourne
 University of Melbourne Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | 01.01.2016 |
Centre for Eye Research Australia
 Centre for Eye Research Australia General GovernmentGovernment Eliminates vision loss and blindness | Direktor/Vorstandsmitglied | 01.03.2017 |
Grattan Institute
 Grattan Institute Miscellaneous Commercial ServicesCommercial Services Develops public policy programs | Direktor/Vorstandsmitglied | 01.01.2019 |
Ehemalige bekannte Positionen von Robert Cuthbertson
| Unternehmen | Position | Ende |
|---|---|---|
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Corporate Officer/Principal | 01.01.1997 |
National Institutes of Health
 National Institutes of Health General GovernmentGovernment Engages in the improvement of health and saving lives | Corporate Officer/Principal | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
68
Beziehungen ersten Grades
8
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 8 |
|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Health Technology |
CSL Innovation Pty Ltd.
 CSL Innovation Pty Ltd. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Health Technology |
CSL Ltd.
 CSL Ltd. BiotechnologyHealth Technology Develops and manufactures medicines that treat people with rare and serious diseases | Health Technology |
University of Melbourne
University of Melbourne Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
National Institutes of Health
National Institutes of Health General GovernmentGovernment Engages in the improvement of health and saving lives | Government |
CSL Behring LLC
CSL Behring LLC BiotechnologyHealth Technology Manufactures and markets plasma protein products | Health Technology |
Centre for Eye Research Australia
Centre for Eye Research Australia General GovernmentGovernment Eliminates vision loss and blindness | Government |
Grattan Institute
Grattan Institute Miscellaneous Commercial ServicesCommercial Services Develops public policy programs | Commercial Services |
